Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare Clinics
Biogen's (NASDAQ: BIIB) drug pipeline took a massive hit earlier this year when the company stopped development of its Alzheimer's disease drug, aducanumab, for a lack of efficacy. Recently, the big biotech reported that it has new data showing aducanumab may work after all. Biogen's shares rallied significantly on the news, but will aducanumab pass muster with regulators? In this episode of Industry Focus: Healthcare, host Shannon Jones and Fool.com contributor Todd Campbell explain why aducanumab was shelved in the first place and whether Biogen's data is good enough to secure an FDA approval.
Also, the pair dig into Walgreens' (NASDAQ: WBA) curious decision to close more than half of its retail healthcare clinics. Does this mean the pharmacy giant is giving up on plans to expand more broadly into healthcare?
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.
Source Fool.com
